WebPurpose: The purpose of this research study is to test the safety and tolerability of an experimental drug, Chemophase, a combination of recombinant human hyaluronidase, (an investigational synthetic enzyme also known as rHuPH20), and mitomycin (MMC) in the treatment of superficial bladder cancer when instilled intravesically immediately after … WebApr 25, 2006 · A Phase 1-2a, Multicenter, Open-Label, Multiple Dose, Safety, Tolerability, and Pharmacokinetic Study of Recombinant Human Hyaluronidase (Chemophase®) in Combination With Mitomycin in Patients With Non-Muscular-Invasive Bladder Cancer
CHEMOPHASE Trademark - Registration Number 3061135 - Serial …
WebApr 14, 2024 · Abstract. Background: Tumor Treating Fields (TTFields) therapy is a loco-regional, noninvasive treatment approved for newly diagnosed (nd)/recurrent (r) glioblastoma (GBM) and mesothelioma. Approval for ndGBM was based on the pivotal phase 3 EF-14 study where TTFields therapy/temozolomide (TMZ), administered in the … WebFiled in April 19 (2004), the CHEMOPHASE covers High dose intravenous formulation of recombinant human hyaluronidase for use as a chemotherapy adjuvant CHEMOPHASE Trademark - Registration Number 3061135 - Serial Number 78404391 :: Justia Trademarks otto dillenberger
FDA Accepts sBLA for Pembrolizumab/Chemo in Gastric or GEJ …
Chemophase is being specifically developed for use with other anticancer drug to increase the local penetration of the anticancer drug for the treatment of superficial bladder cancer. In this study, Chemophase will be given in combination with mitomycin C directly into the bladder. Mitomycin C is an anti-tumor drug that is commonly used to ... http://halozyme2015.q4web.com/investors/news-releases/news-release-details/2007/Halozyme-Therapeutics-Completes-Enrollment-in-Chemophase-Phase-IIIa-Clinical-Trial-for-Superficial-Bladder-Cancer/default.aspx#! WebClose the Gap. SurvivorNetTV. Clinical Trials イオン結晶 水 性質